Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYD-1,3 dengue vaccine + CYD-2,4 dengue vaccine
- Development stage
- Discontinued
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CYD-1,3 dengue vaccine + CYD-2,4 dengue vaccine is a bivalent dengue vaccination strategy developed by Sanofi Pasteur using the ChimeriVax-Dengue (CYD) platform. This approach involves the sequential administration of two bivalent formulations: one targeting dengue serotypes 1 and 3 (CYD-1,3) followed by another targeting serotypes 2 and 4 (CYD-2,4). The vaccine is based on a live attenuated yellow fever 17D virus backbone, where the genes for the pre-membrane and envelope proteins are replaced with corresponding sequences from wild-type dengue viruses. Investigated in Phase IIa clinical trials in Mexico (2008-2009) as a potential alternative to the tetravalent CYD-TDV (Dengvaxia), the strategy was found to offer no immunogenic advantage, as the second injection elicited only a low immune response against serotypes 2 and 4.
- Other names
- bivalent CYD vaccineCYD-1;3 + CYD-2;4bivalent dengue vaccination strategy
02
Targets
E (Tick-borne encephalitis virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on CYD-1,3 dengue vaccine + CYD-2,4 dengue vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYD-1,3 dengue vaccine + CYD-2,4 dengue vaccine.